Will US, Europe work together on AI regulation?

Michael Walter | | Health Exec | Policy & Regulations
Globe

Sundar Pichai, who serves as the CEO for both Alphabet and Google, wants the United States and European Union to work together on developing AI regulations. Is there any chance such cooperation will occur?

As reported by Fortune, Pichai said “there is no question in my mind that artificial intelligence needs to be regulated” and shared his hope that guidelines would balance “potential harms with social opportunities.”

A.I. needs to be regulated: Google CEO calls for coordinated U.S.-EU rules

In the past, the United States has pushed to develop its own AI guidelines without minimal input from other countries. In addition, the White House recently shared a new set of principles for governing AI development solutions, pushing for a limited regulatory approach and the use of fair, unbiased algorithms. The EU is expected to share its own plans for legislating AI in the near future.

Click the link below for the full story from Fortune:

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.